Cited by 134Pain Mechanisms and TreatmentsCannabis and Cannabinoid ResearchIon Channels and Receptors

Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids

Open access
Wallace, Victoria C. J., Cottrell, David F., Brophy, Peter J., Fleetwood-Walker, Susan M.·2003·The Journal of Neuroscience

Abstract

Demyelinating diseases can be associated with painful sensory phenomena such as tactile allodynia and hyperalgesia. To study the mechanisms underlying demyelination-induced pain, we have characterized a novel model of demyelination of the sciatic or saphenous nerve. Topical lysolecithin application causes focal demyelination of afferent nerve A-fibers without axonal loss, as assessed either by electron and light microscopy or by immunohistochemical analysis of dorsal root ganglia (DRG) for a neuronal injury marker, activating transcription factor 3. Focal demyelination is accompanied by spontaneous action potentials in afferents and increased expression of neuropeptide Y and Na(v)1.3 sodium channels specifically in DRG neurons that coexpress a specific marker of myelinated afferents. In contrast, expression of tetrodotoxin-resistant, Na(v)1.8 sodium channels is specifically decreased in the same subgroup of DRG cells. Central sensitization of somatosensory processing is also induced, with increased behavioral reflex responsiveness to thermal and mechanical stimuli. These changes are reversed by intrathecal administration of an NMDA receptor antagonist or cannabinoid (CB) receptor agonist, but not by a mu-opioid receptor agonist. Recovery of behavioral reflexes occurred approximately 3 weeks after lysolecithin treatment. This is the first time that demyelination of afferent A-fibers has been shown to specifically induce neuropathic pain and indicates that axonal damage is not a prerequisite for development of the pain state. The profile of phenotypic changes in DRG is distinct from other pain models and displays a sensitivity to NMDA and CB receptor agents that may be exploitable therapeutically.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.23-08-03221.2003

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the lysolecithin-induced demyelination model, heightened sensitivity to non-noxious and noxious mechanical stimulation emerged 5 days post-exposure and peaked between 9-15 days, with recovery to baseline by day 23.

    “Heightened sensitivity to both non-noxious and noxious mechanical stimulation is observed in lysolecithin-treated rats; this hypersensitivity emerged 5 days post-exposure and peaked between 9-15 days post-exposure.125 Recovery to baseline levels was observed by day 23 post-lysolecithin.”
  • The anti-hyperalgesic and anti-allodynic effects of WIN55,212-2 were reversed by a CB1-specific antagonist in both tests.

    “Notably, the anti-hyperalgesic and anti-allodynic effects of WIN55,212-2 were reversed by a CB1-specific antagonist in both tests.”
  • DAMGO failed to produce an effect in the lysolecithin-induced demyelination model.

    “By contrast, DAMGO failed to produce an effect.”
  • WIN55,212-2 attenuated mechanical allodynia and thermal hyperalgesia in the lysolecithin model and remained efficacious for up to one hour post injection.

    “WIN55,212-2 attenuated mechanical allodynia and thermal hyperalgesia in this model and remained efficacious for up to one hour post injection.125”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Wilcox GL (1991) Excitatory neurotransmitters and pain. In: Proceedings of the 6th World Congress of Pain (Bond MR, Charlton JE, Woolf CJ, eds), pp 97-117. Amsterdam: Elsevier.

Cited by

Sorted by citations

Authors
Wallace, V. C. J., Cottrell, D. F., Brophy, P. J., & Fleetwood-Walker, S. M.
Affiliations
University of Edinburgh (GB)
Venue
The Journal of Neuroscience
Published
2003-04-15
Volume
23
Issue
8
Pages
3221-3233
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2103425524
Cited by
134
References
105
Citations by year
2025: 1 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 1 · 2013: 8 · 2012: 9
FWCI
4.60
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • Wellcome Trust
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
Keywords
peripheral neuropathic pain, sciatic nerve, saphenous nerve, dorsal root ganglia, neuropeptide Y, Nav1.8 sodium channel, central sensitization, NMDA receptor antagonists, cannabinoid receptor agonists, mu-opioid receptor, mechanical allodynia, hyperalgesia
MeSH terms
Action Potentials, Animals, Behavior, Animal, Cannabinoids, Demyelinating Diseases, Disease Models, Animal, Drug Administration Routes, Ganglia, Spinal, Immunohistochemistry, Lysophosphatidylcholines, Mice, Inbred C57BL, Nerve Fibers, Myelinated, Neurons, Afferent, Neuropeptide Y, Pain, Peripheral Nerves, Reflex, Sciatic Nerve, Sodium Channels, Receptors, N-Methyl-D-Aspartate, Receptors, Opioid, mu, Excitatory Amino Acid Antagonists, Mononeuropathies, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review